PER-013-14未知未知
Study 117106: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients
GlaxoSmithKline,0 个研究点目标入组 75 人开始时间: 2014年6月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 40 至 100（—）
入选标准
- •1. COPD diagnosis: Subjects with a clinically documented history of COPD for at least 1 year in accordance with the following definition by the American Thoracic Society/European Respiratory Society [Celli, 2004]
- •2. Severity of COPD: Subjects must present with the following:
- •A measured pre and post-salbutamol FEV1/FVC ratio of <0.70 at Visit 1 to confirm the diagnosis of COPD
- •A measured post-salbutamol FEV1> 20% and ≤80% of predicted normal values calculated using NHANES III reference equations [Hankinson 1999, Hankinson, 2010] at Visit 1
- •3. History of exacerbations: A well documented history (e.g., medical record verification) in the 12 months prior to Visit 1 of:
- •at least two moderate COPD exacerbations. Moderate is defined as the use of systemic corticosteroids (intramuscular (IM), intravenous, or oral) and/or treatment with antibiotics.
- •at least one severe COPD exacerbation. Severe is defined as having required hospitalization
- •Note: At least one exacerbation must have occurred while the subject was taking ICS plus LABA plus LAMA.
- •Note: Prior use of antibiotics alone does not qualify as a moderate exacerbation unless the use was specifically for the treatment of worsening symptoms of COPD.
- •4. Concomitant COPD therapy: A well documented requirement for optimized standard of care (SoC) background therapy that includes ICS plus 2 additional COPD medications (i.e., triple therapy) for the 12 months prior to Visit 1 and meets the following criteria
排除标准
- •1. Asthma:
- •Current and Former Smokers: Subjects with a current diagnosis of asthma (those with a prior history are eligible if they meet inclusion criteria for a current diagnosis of COPD)
- •Never-Smokers: Subjects with any history of asthma
- •2. Other respiratory disorders: The investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease. Subjects with α1-antitrypsin deficiency as the underlying cause of COPD are excluded. Also, excluded are subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases. Subjects are also excluded if maintenance use of bi-level positive airway pressure is required for the treatment of respiratory disorder. 3. COPD stability: Subjects with pneumonia, exacerbation, lower respiratory infection within the 4 weeks prior to Visit 1. 4. Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Visit 1.
- •5. Pulmonary rehabilitation program: Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded.
- •6. Oxygen: Subjects receiving treatment with oxygen more than 4.0L/min. While breathing supplemental oxygen, subjects should demonstrate an oxyhemoglobin saturation greater than or equal to 89%.
研究者
相似试验
进行中（未招募）
1 期
Study evaluating safety and efficacy of mepolizumab in the treatment of COPD patients with frequent exacerbations.Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbations.MedDRA version: 16.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2013-004298-28-ESGlaxoSmithKline, S.A.800
进行中（未招募）
1 期
English Study evaluating safety and efficacy of mepolizumab in the treatment of COPD patients with frequent exacerbations.Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbationsMedDRA version: 18.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2013-004297-98-NLGlaxoSmithKline Research & Development Ltd660
已完成
3 期
Study 117113: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil levelNL-OMON44215GlaxoSmithKline38
进行中（未招募）
1 期
English Study evaluating safety and efficacy of mepolizumab in the treatment of COPD patients with frequent exacerbations.Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbationsMedDRA version: 19.0Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2013-004297-98-DEGlaxoSmithKline Research & Development Ltd660
进行中（未招募）
1 期
English Study evaluating safety and efficacy of mepolizumab in the treatment of COPD patients with frequent exacerbations.EUCTR2013-004297-98-GBGlaxoSmithKline Research & Development Ltd660